MSMEs in pharma: Why revenue growth for the sector in FY22 may dip despite Covid vaccine opportunity-Business Journal

Ease of Doing Business for MSMEs: Indian pharmaceuticals (pharma) sector, which has MSMEs as its key growth driver, is staring at shrinking revenue growth and decline in operating profitability this financial year (FY), according to market experts. Slower growth in exports, higher prices of raw materials known as active pharmaceutical ingredients (API) or bulk drugs, shipment challenges including container shortage, rising input cost for corrugated box makers, and more are likely to cost pharma businesses this fiscal growth. The impact assumes significance as the sector had leveraged Covid-induced opportunity in selling Covid-related vaccines and drugs to other countries.
“Exports have …

Read the source article at Business News
2021-11-17 03:30:00